Lamivudine

🧮 Dose calculator

HIV-1 infection (treatment) · Regimen source: FDA Lamivudine · 2.1

• • Always in combination with other antiretrovirals. FDA Lamivudine · 2.1

Enter age (weight is optional for this regimen).

👥 Special populations

• 🤰 PregnancyUse with caution

  Label: pregnancy registry data show no increase in birth defects over the background rate. FDA Lamivudine · 8.1

  “Available data from the APR show no difference in the overall risk of birth defects for lamivudine compared with the background rate for birth defects of 2.7% in the Metropolitan Atlanta Congenital Defects Program (MACDP) reference population.”

• 🤱 BreastfeedingUse with caution

  Label: use with caution while breastfeeding; see the label text. FDA Lamivudine · 8.2

  “Risk Summary The Centers for Disease Control and Prevention recommends that HIV-1-infected mothers in the United States not breastfeed their infants to avoid risking postnatal transmission of HIV-1 infection.”

• 👶 ChildrenUse with caution

  The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Lamivudine · 8.4

  “The safety and effectiveness of lamivudine tablets in combination with other antiretroviral agents have been established in pediatric patients aged 3 months and older.”

• 👴 Older adultsUse with caution

  Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Lamivudine · 8.5

  “In general, caution should be exercised in the administration of lamivudine in elderly patients reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy [see Dosage and Administration ( 2.3 ), Clinical Pharmacology ( 12.3 )].”

• ⚥ Females & males of reproductive potentialNo data

  The source for this drug has no section for this group.